Inozyme Total Assets from 2010 to 2024

INZY Stock

USD 2.71 0.01 0.37%

Inozyme Pharma Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 132.8 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2019-12-31

Previous Quarter

155.7 M

Current Value

143.4 M

Quarterly Volatility

41.1 M

Covid

Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.3 M, Interest Income of 4.3 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.65. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.

Check out the analysis of Inozyme Pharma Correlation against competitors.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Total Assets Growth Pattern

Below is the plot of the Total Assets of Inozyme Pharma over the last few years. Total assets refers to the total amount of Inozyme Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Inozyme Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Inozyme Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 200.85 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Inozyme Total Assets Regression Statistics

	Arithmetic Mean	80,372,648
	Geometric Mean	66,286,310
	Coefficient Of Variation	69.57
	Mean Deviation	48,519,397
	Median	43,543,000
	Standard Deviation	55,912,120
	Sample Variance	3126.2T
	Range	157.3M
	R-Value	0.79
	Mean Square Error	1284.2T
	R-Squared	0.62
	Significance	0.0005
	Slope	9,832,950
	Total Sum of Squares	43766.3T

Inozyme Total Assets History

	2024	132.8 M
	2023	200.8 M
	2022	139.2 M
	2021	123.5 M
	2020	169.4 M
	2019	47.9 M

Other Fundumenentals of Inozyme Pharma

Intangibles To Total Assets

Inozyme Pharma Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Capital Surpluse	Total Liab	Deferred Long Term Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Long Term Investments	Short Term Debt	Long Term Debt	Long Term Debt Total
Total Assets		0.98	0.97	-0.05	-0.88	0.74	0.78	1.0	0.94	-0.63	0.87	0.99	1.0	1.0	0.82	0.82	0.78	-0.77	0.8	0.67	-0.51
Total Stockholder Equity	0.98		1.0	-0.16	-0.83	0.85	0.67	0.97	0.93	-0.79	0.82	0.99	0.96	0.96	0.73	0.88	0.76	-0.75	0.76	0.51	-0.41
Net Tangible Assets	0.97	1.0		-0.18	-0.81	0.86	0.63	0.97	0.91	-0.79	0.82	0.99	0.96	0.95	0.7	0.88	0.76	-0.74	0.75	0.48	-0.37
Net Debt	-0.05	-0.16	-0.18		-0.38	-0.42	0.32	-0.03	0.17	0.35	0.02	-0.08	0.0	-0.01	0.42	-0.03	0.46	-0.5	0.5	0.49	-0.49
Retained Earnings	-0.88	-0.83	-0.81	-0.38		-0.57	-0.89	-0.89	-0.97	0.49	-0.8	-0.86	-0.9	-0.89	-0.97	-0.73	-0.89	0.94	-0.95	-0.78	0.75
Accounts Payable	0.74	0.85	0.86	-0.42	-0.57		0.35	0.73	0.74	-0.95	0.64	0.78	0.7	0.69	0.44	0.82	0.5	-0.55	0.51	0.04	-0.18
Net Receivables	0.78	0.67	0.63	0.32	-0.89	0.35		0.78	0.84	-0.23	0.69	0.72	0.8	0.81	0.94	0.5	0.61	-0.7	0.72	0.9	-0.9
Short Term Investments	1.0	0.97	0.97	-0.03	-0.89	0.73	0.78		0.94	-0.63	0.89	0.99	1.0	1.0	0.81	0.84	0.8	-0.78	0.81	0.67	-0.51
Capital Surpluse	0.94	0.93	0.91	0.17	-0.97	0.74	0.84	0.94		-0.67	0.82	0.94	0.94	0.94	0.92	0.83	0.85	-0.9	0.9	0.67	-0.68
Total Liab	-0.63	-0.79	-0.79	0.35	0.49	-0.95	-0.23	-0.63	-0.67		-0.44	-0.71	-0.6	-0.59	-0.37	-0.81	-0.48	0.54	-0.49	0.03	0.14
Deferred Long Term Liab	0.87	0.82	0.82	0.02	-0.8	0.64	0.69	0.89	0.82	-0.44		0.84	0.87	0.87	0.68	0.78	0.76	-0.72	0.75	0.54	-0.38
Net Invested Capital	0.99	0.99	0.99	-0.08	-0.86	0.78	0.72	0.99	0.94	-0.71	0.84		0.99	0.99	0.78	0.86	0.79	-0.77	0.8	0.61	-0.46
Total Current Assets	1.0	0.96	0.96	0.0	-0.9	0.7	0.8	1.0	0.94	-0.6	0.87	0.99		1.0	0.84	0.81	0.8	-0.78	0.82	0.7	-0.53
Net Working Capital	1.0	0.96	0.95	-0.01	-0.89	0.69	0.81	1.0	0.94	-0.59	0.87	0.99	1.0		0.83	0.8	0.79	-0.77	0.8	0.71	-0.53
Common Stock	0.82	0.73	0.7	0.42	-0.97	0.44	0.94	0.81	0.92	-0.37	0.68	0.78	0.84	0.83		0.57	0.78	-0.86	0.87	0.85	-0.86
Property Plant Equipment	0.82	0.88	0.88	-0.03	-0.73	0.82	0.5	0.84	0.83	-0.81	0.78	0.86	0.81	0.8	0.57		0.78	-0.79	0.76	0.35	-0.33
Current Deferred Revenue	0.78	0.76	0.76	0.46	-0.89	0.5	0.61	0.8	0.85	-0.48	0.76	0.79	0.8	0.79	0.78	0.78		-0.96	0.98	0.61	-0.44
Long Term Investments	-0.77	-0.75	-0.74	-0.5	0.94	-0.55	-0.7	-0.78	-0.9	0.54	-0.72	-0.77	-0.78	-0.77	-0.86	-0.79	-0.96		-0.99	-0.62	0.61
Short Term Debt	0.8	0.76	0.75	0.5	-0.95	0.51	0.72	0.81	0.9	-0.49	0.75	0.8	0.82	0.8	0.87	0.76	0.98	-0.99		0.68	-0.59
Long Term Debt	0.67	0.51	0.48	0.49	-0.78	0.04	0.9	0.67	0.67	0.03	0.54	0.61	0.7	0.71	0.85	0.35	0.61	-0.62	0.68		-0.8
Long Term Debt Total	-0.51	-0.41	-0.37	-0.49	0.75	-0.18	-0.9	-0.51	-0.68	0.14	-0.38	-0.46	-0.53	-0.53	-0.86	-0.33	-0.44	0.61	-0.59	-0.8

Click cells to compare fundamentals

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	200.8 M	132.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC